1. Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes. Issue 6 (25th March 2015) Authors: Pacini, G.; Mari, A.; Fouqueray, P.; Bolze, S.; Roden, M. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 6(2015:Jun.) Page Start: 541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes. Issue 6 (25th March 2015) Authors: Pacini, G.; Mari, A.; Fouqueray, P.; Bolze, S.; Roden, M. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 6(2015:Jun.) Page Start: 541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SOC-II-07 PXL065, the deuterium-stabilized (R)-enantiomer of pioglitazone, shows an improved embryo-fetal development safety profile vs. pioglitazone racemate. (1st September 2022) Authors: Giorgi, H.; Verchère-Beau, C.; Mazuir, F.; Bolze, S. Journal: Toxicology letters Issue: Volume 368(2022)supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗